Amgen Inc. (AMGN)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Robert A. Bradway
|
Chairman & CEO | 6.69M | -- | 1963 |
|
Mr. Murdo Gordon
|
Executive Vice President of Global Markets and Policy | 3.22M | -- | 1967 |
|
Mr. Peter H. Griffith
|
Executive Vice President | 3.31M | -- | 1959 |
|
Dr. James E. Bradner M.D.
|
EVP of Research & Development, Artificial Intelligence and Data | 3.84M | -- | 1972 |
|
Mr. Thomas J. W. Dittrich
|
Executive VP & CFO | -- | -- | 1964 |
|
Mr. Esteban Santos
|
Executive Vice President of Operations | 3.01M | -- | 1968 |
|
Mr. Matthew C. Busch
|
Chief Accounting Officer & VP of Finance | -- | -- | 1975 |
|
Mr. Sean Bruich
|
SVP & Chief Technology Officer | -- | -- | -- |
|
Mr. Scott Skellenger
|
Senior VP & Chief Information Officer | -- | -- | -- |
|
Mr. Howard Y. Chang M.D., Ph.D.
|
Senior VP of Global Research & Chief Scientific Officer | -- | -- | -- |
Amgen Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 31,500
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Corporate Governance
Upcoming Events
November 3, 2026 at 8:00 PM UTC
Amgen Inc. Earnings Date
Recent Events
September 11, 2026 at 12:00 AM UTC
Dividend Date
August 21, 2026 at 12:00 AM UTC
Ex-Dividend Date
